Hims · Individual product review
Hims 3-in-1 Pill review
Hims 3-in-1 Pill: a pill dosage form with the same ingredient names as one Hard Mints formula, with formulation, cost, evidence and availability examined to monitor the offer, the evidence and the plan after prescribing.
The ED Watch editorial desk · Published October 7, 2026 · Updated October 7, 2026
AI-assisted public-document research · Not medically reviewed · No firsthand product testing
We may earn a commission through commercial links. This review does not award a clinical rating. Read the disclosure.
Hims 3-in-1 Pill deserves a review separate from the Hims service because it identifies a pill containing sildenafil, tadalafil and B12. The relevant questions concern this preparation's evidence, complete cost and follow-up, not a single score for everything the company sells. This product watch records what the current public material can establish and what still needs confirmation.
The exact product
The feature to watch is a pill dosage form with the same ingredient names as one Hard Mints formula. Match the full ingredient list and dosage form to the prescription actually offered. A company may market conventional tablets, daily products and compounds simultaneously. A service review can describe access or billing while leaving the differences between those medicines unresolved. The identity record below is therefore the starting point for interpreting every price or clinical claim on this page.
| Provider | Hims |
|---|---|
| Listed active ingredients | Sildenafil + tadalafil + vitamin B12 |
| Dosage form | Compounded pill |
| Regulatory distinction | Compounded preparation; the finished product is not FDA-approved. |
| Source basis | Hims: 3-in-1 Pill formulation and safety · Hims: current ED treatment catalog |
Price, supply and payment
The public cost entry is From $35/month. Watch the payment interval and supplied quantity as closely as the headline. An introductory amount, an approximate article example and a complete renewal quote have different evidentiary value. Do not combine a unit figure from one plan with a monthly banner from another. Save the selected order terms so that a later refill or treatment change can be checked against them.
| Catalog starting figure | From $35/month |
|---|---|
| Formulation record | Hims dedicated 3-in-1 Pill safety information |
| Important distinction | Matching ingredients do not establish matching strengths or absorption |
| Approval | Compounded finished preparation; not FDA-approved |
What the research can support
The research relevant to the offer concerns ingredient evidence; no equivalence study between the pill and chew verified. It leaves exact strengths and the selected billing commitment unverified. That boundary prevents ingredient studies or provider satisfaction surveys from turning into finished-product efficacy scores. Ask whether a quoted timing or performance result measured the exact preparation and a clinically relevant outcome. A useful review can recognize an evidence gap without asserting that an unstudied product must be ineffective.
| Evidence boundary | ingredient evidence; no equivalence study between the pill and chew verified |
|---|---|
| Not established here | exact strengths and the selected billing commitment |
| Clinical and regulatory references | Cui et al. (2015): daily tadalafil with as-needed sildenafil · MedlinePlus: Tadalafil · DailyMed: Tadalafil prescribing information, including section 5.11 · FDA: Compounding and the FDA — questions and answers · MedlinePlus: Sildenafil |
Safety questions for the prescriber
Monitoring starts with accurate prescribing information. Disclose nitrates or recreational nitrites, riociguat, other ED medicines, blood-pressure treatment and relevant heart, kidney, liver or eye history. Do not add Hims 3-in-1 Pill to an existing regimen without individualized instructions. The ingredient-specific consideration below should be addressed before a treatment change, not discovered only after an automatic refill has created overlapping supplies.
| Multiple PDE5 inhibitors | Standard tadalafil labeling advises against combining PDE5 inhibitors; individualized rationale and monitoring are needed. |
|---|---|
| Added nutrients | Review actual amounts and duplicate supplements; nutrient inclusion does not prove improved ED efficacy. |
Availability and the actual prescription
The current availability finding is Public product listing; individual eligibility and current prescription require confirmation. Treat this as a dated documentary observation. Account eligibility and product catalogs can change, while public safety pages may remain accessible. Confirm the actual offered medicine, quantity and pharmacy instructions when enrolling or switching. A reachable page is not evidence that a new prescription or new-customer plan has been approved.
Refills, changes and cancellation
The next step to watch is the response review. Record whether the original concern improved, what unwanted effects occurred and whether the instructions were followed. Ask the clinician “Why choose this pill instead of a single-ingredient tablet or the chew?” Then confirm any treatment change in the next shipment and billing record. Administrative cancellation and clinical stopping instructions are separate states; one should not be inferred from the other.
| Next charge | The next order date is the charge/processing date; a first refill can be scheduled early. |
|---|---|
| Cancellation notice | At least 48 hours before the next order, according to support guidance. |
| Already processing | Ending a subscription does not cancel an order already processing or shipped. |
| Refund boundary | No refund guaranteed after pharmacy processing. |
| Policy sources | Hims Support: canceling a subscription · Hims Support: refund policy · Hims Support: when billing occurs |
Compare named products
Use the linked alternatives to examine a concrete change in ingredient, form, schedule or commitment. They are not ordered by clinical superiority. A provider's customer-service features cannot establish the efficacy of a medicine, and a medicine's established evidence cannot verify one provider's delivery or prescribing quality. Keep those judgments separate when deciding what to investigate next.
Questions to keep with the offer
This watch is based on public-source research, with no medical reviewer and no firsthand trial of Hims 3-in-1 Pill. We have not tested the checkout, medicine, support response or refund process. The cited records explain the advertised offer and evidence limits. Personal suitability, a complete accepted quote and a workable monitoring plan still require the responsible clinical and service teams.
| Ask about this formula | Why choose this pill instead of a single-ingredient tablet or the chew? |
|---|---|
| Ask about the payment | What are the exact quantity, total due now, renewal amount and notice deadline? |
| Ask about a change | Who confirms the medical instructions, pharmacy order and next account charge? |
When to get urgent help
An erection lasting more than four hours or chest pain requires emergency care. Tell the treating clinician what was taken and when.
Sudden hearing or vision loss needs prompt medical attention. Do not wait for an ordinary account-support reply.
Original sources
Provider pages document an advertised offer. Regulatory records and studies address different questions; an ingredient study does not establish a finished compounded product's outcomes.
- Hims: 3-in-1 Pill formulation and safetyProvider formulation document; sildenafil, tadalafil and vitamin B12 · Checked 2026-10-07
- Hims: current ED treatment catalogProvider catalog; individual named offers and starting prices · Checked 2026-10-07
- Hims Support: canceling a subscriptionProvider policy; 48-hour notice and orders already processing · Checked 2026-10-07
- Hims Support: refund policyProvider policy; no guaranteed refund after pharmacy processing · Checked 2026-10-07
- Hims Support: when billing occursProvider policy; next order date, charge timing, and subscription intervals · Checked 2026-10-07
- Hims Support: changing the next order dateProvider support; refill rescheduling differs from cancellation · Checked 2026-10-07
- Cui et al. (2015): daily tadalafil with as-needed sildenafilPrimary clinical study; 180 patients, specific regimen, abstract reviewed via NCBI · Checked 2026-10-07
- MedlinePlus: TadalafilDrug information; standard tadalafil products · Checked 2026-10-07
- DailyMed: Tadalafil prescribing information, including section 5.11Prescribing label; not evidence for the 4Play combination · Checked 2026-10-07
- FDA: Compounding and the FDA — questions and answersGovernment guidance on compounded medications · Checked 2026-10-07
- MedlinePlus: SildenafilDrug information; standard sildenafil products · Checked 2026-10-07